298 related articles for article (PubMed ID: 32120017)
41. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
42. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway.
Zhang DD; Lo SC; Sun Z; Habib GM; Lieberman MW; Hannink M
J Biol Chem; 2005 Aug; 280(34):30091-9. PubMed ID: 15983046
[TBL] [Abstract][Full Text] [Related]
43. Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells.
Baird L; Dinkova-Kostova AT
Biochem Biophys Res Commun; 2013 Mar; 433(1):58-65. PubMed ID: 23454126
[TBL] [Abstract][Full Text] [Related]
44. Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway.
Richardson BG; Jain AD; Speltz TE; Moore TW
Bioorg Med Chem Lett; 2015 Jun; 25(11):2261-8. PubMed ID: 25937010
[TBL] [Abstract][Full Text] [Related]
45. Development of a High-Throughput Cul3-Keap1 Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for Identifying Nrf2 Activators.
Poore DD; Hofmann G; Wolfe LA; Qi H; Jiang M; Fischer M; Wu Z; Sweitzer TD; Chakravorty S; Donovan B; Li H
SLAS Discov; 2019 Feb; 24(2):175-189. PubMed ID: 30383469
[TBL] [Abstract][Full Text] [Related]
46. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.
Suzuki T; Yamamoto M
J Biol Chem; 2017 Oct; 292(41):16817-16824. PubMed ID: 28842501
[TBL] [Abstract][Full Text] [Related]
47. Nrf2, the Major Regulator of the Cellular Oxidative Stress Response, is Partially Disordered.
Karunatilleke NC; Fast CS; Ngo V; Brickenden A; Duennwald ML; Konermann L; Choy WY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299054
[TBL] [Abstract][Full Text] [Related]
48. Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells.
Zhou B; Zhang X; Wang G; Barbour KW; Berger FG; Wang Q
Bioorg Med Chem; 2019 Jan; 27(1):92-99. PubMed ID: 30473361
[TBL] [Abstract][Full Text] [Related]
49. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
50. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
[TBL] [Abstract][Full Text] [Related]
51. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1.
Lo SC; Hannink M
Mol Cell Biol; 2006 Feb; 26(4):1235-44. PubMed ID: 16449638
[TBL] [Abstract][Full Text] [Related]
52. The molecular mechanism of Nrf2-Keap1 signaling pathway in the antioxidant defense response induced by BaP in the scallop Chlamys farreri.
Wang H; Pan L; Xu R; Si L; Zhang X
Fish Shellfish Immunol; 2019 Sep; 92():489-499. PubMed ID: 31220575
[TBL] [Abstract][Full Text] [Related]
53. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase.
Cullinan SB; Gordan JD; Jin J; Harper JW; Diehl JA
Mol Cell Biol; 2004 Oct; 24(19):8477-86. PubMed ID: 15367669
[TBL] [Abstract][Full Text] [Related]
54. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.
Eggler AL; Small E; Hannink M; Mesecar AD
Biochem J; 2009 Jul; 422(1):171-80. PubMed ID: 19489739
[TBL] [Abstract][Full Text] [Related]
55. Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity.
Lu MC; Zhang X; Wu F; Tan SJ; Zhao J; You QD; Jiang ZY
J Med Chem; 2019 Jul; 62(14):6796-6813. PubMed ID: 31283229
[TBL] [Abstract][Full Text] [Related]
56. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
57. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.
Martinez VD; Vucic EA; Thu KL; Pikor LA; Hubaux R; Lam WL
Biomed Res Int; 2014; 2014():159459. PubMed ID: 25114896
[TBL] [Abstract][Full Text] [Related]
58. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract][Full Text] [Related]
59. CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases.
Wang P; Song J; Ye D
Adv Exp Med Biol; 2020; 1217():211-223. PubMed ID: 31898230
[TBL] [Abstract][Full Text] [Related]
60. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
